• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by OTR Acquisition Corp.

    5/18/22 9:29:25 AM ET
    $OTRA
    Get the next $OTRA alert in real time by email
    425 1 tm2215943d1_8k.htm 425

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 17, 2022

     

     

    OTR ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39708   85-2136914
    (State or other jurisdiction of   (Commission   (I.R.S. Employer
    incorporation or organization)   File Number)    Identification Number)

     

    1395 Brickell Avenue, Suite 800

    Miami, Florida
      33131
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (305) 697-9600

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

     

    x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant   OTRAU   The NASDAQ Stock Market LLC
    Class A Common Stock, par value $0.0001 per share   OTRA   The NASDAQ Stock Market LLC
    Warrants, each exercisable for one share of Class A Common Stock for $11.50 per share   OTRAW   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

     

     

     

     

     

    Item 8.01Other Events.

     

    As of May 17, 2022, holders of an aggregate of 9,769,363 shares of Class A Common Stock (the “Common Stock”), out of the 10,447,350 shares of Common Stock subject to redemption, of OTR Acquisition Corp., a Delaware corporation (the “Company”) have redeemed their shares of Common Stock in connection with the proposed business combination with Comera Life Sciences, Inc (“Comera”) (the “Business Combination”). The Company is no longer allowing holders of Common Stock to reverse their election to have their shares of Common Stock redeemed. As a result, there are 677,987 shares of Common Stock outstanding that were subject to redemption but not redeemed.

     

    The Company anticipates that the closing of the Business Combination will occur on or before May 19, 2022, subject to the satisfaction or waiver of all of the requirements to closing.

     

    Important Information About the Proposed Business Combination and Where to Find It

     

    In connection with the proposed Business Combination, Comera Life Sciences Holdings, Inc. (“Holdco”) filed the Registration Statement which includes a proxy statement of the Company and a prospectus of Holdco, which registration statement was declared effective by the SEC on April 11, 2022. The definitive proxy statement/prospectus was sent to all Company and Comera stockholders. Holdco and the Company will also file other documents regarding the proposed Business Combination with the SEC. Before making any voting decision, investors and securities holders of the Company and Comera are urged to read the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed Business Combination as they become available because they contain or will contain important information about the proposed Business Combination and the parties to the proposed Business Combination.

     

    Investors and securities holders may obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Holdco through the website maintained by the SEC at https://sec.gov/. In addition, the documents filed by the Company may be obtained free of charge from the Company’s website at https://otracquisition.com/investors/ or by written request to OTR Acquisition Corp., 1395 Brickell Avenue, Suite 800, Miami, Florida 33131.

     

    Participants in the Solicitation

     

    Holdco, the Company and Comera and their respective directors and officers may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the proposed Business Combination. Information about the Company’s directors and executive officers and their ownership of the Company’s securities is set forth in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on March 8, 2022. To the extent that holdings of the Company’s securities have changed since the amounts printed in the Company’s Annual Report, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed Business Combination may be obtained by reading the proxy statement/prospectus regarding the proposed Business Combination. You may obtain free copies of these documents as described in the preceding paragraph.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: May 18, 2022

     

      OTR ACQUISITION CORP.
         
      By: /s/ Nicholas J. Singer
      Name: Nicholas J. Singer
      Title: Chief Executive Officer

     

     

     

    Get the next $OTRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Gray Glenn Evan converted options into 22,123 shares and disposed of 100,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:37:26 PM ET
    $OTRA

    SEC Form 4: Otr Acquisition Sponsor Llc converted options into 1,305,918 shares and disposed of 1,305,918 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:35:50 PM ET
    $OTRA

    SEC Form 4: Besner Nadav converted options into 5,000 shares and disposed of 5,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:36:27 PM ET
    $OTRA

    $OTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics

    – Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb

    5/20/22 8:00:00 AM ET
    $OTRA
    $OTRAU
    Business Services
    Finance

    Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation

    Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c

    5/9/22 8:00:00 AM ET
    $OTRA

    Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo

    Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202

    4/27/22 8:00:00 AM ET
    $OTRA

    $OTRA
    SEC Filings

    View All

    SEC Form 15-12B filed by OTR Acquisition Corp.

    15-12B - OTR Acquisition Corp. (0001821318) (Filer)

    5/31/22 8:00:30 AM ET
    $OTRA

    OTR Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OTR Acquisition Corp. (0001821318) (Filer)

    5/24/22 4:31:11 PM ET
    $OTRA

    SEC Form 25-NSE filed by OTR Acquisition Corp.

    25-NSE - OTR Acquisition Corp. (0001821318) (Subject)

    5/19/22 4:06:33 PM ET
    $OTRA

    $OTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    1/24/23 9:57:09 AM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/20/22 4:37:55 PM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/10/22 4:19:44 PM ET
    $OTRA